08:25 AM EDT, 06/23/2025 (MT Newswires) -- CorMedix ( CRMD ) said Monday that its large dialysis organization customer has begun ordering and will start implementing DefenCath in H2 2025, targeting at least 50% more patients than previously planned.

The company said it had amended its agreement with the organization to reflect this broader rollout, which is expected to contribute modestly to June revenue and drive stronger growth in the second half of the year.

Due to the expanded implementation, CorMedix ( CRMD ) has raised its Q2 net sales guidance to a range of $35 million to $40 million from $31 million.

Shares of the company were up 15.5% in Monday's premarket activity.